3rd Annual SMi Cancer Vaccines Conference London 2014: Pre-clinical Entities

  • Conference Call
  • SMi present the 3rd Annual Can­cer Vac­cines Con­fer­ence tak­ing place in Lon­don, United King­dom on Mon­day 15th and Tues­day 16th Sep­tem­ber 2014 at the Hol­i­day Inn Regents Park.

    This year’s event will focus on the pre-​clinical enti­ties that are cru­cial when mov­ing for­ward in clin­i­cal tri­als. This will include, assess­ing anti­gen dis­cov­ery and genome sequenc­ing in addi­tion to eval­u­at­ing bio­mark­ers and chimeric anti­gen receptors.

    There is a grow­ing demand for com­bi­na­tion ther­a­pies and assess­ing clin­i­cal trial design, espe­cially with fail­ures in the clinic increas­ing, the ques­tion to be asked is how can we learn from this and move for­ward to ensure phase III devel­op­ments and reg­u­la­tory approval?

    The agenda will focus on in vivo tar­get­ing of anti­gens to den­dritic cells for ther­a­peu­tic anti-​cancer vac­cines, review­ing pre­ven­tive vac­cine novel adju­vants pro­grammes aswell as eval­u­at­ing patient stratification.

    Fur­ther­more, it will enable a broad range of aca­d­e­mics, small biotechs and large phar­ma­ceu­ti­cal com­pa­nies to review­an­a­lyt­i­cal meth­ods to enable reli­a­bil­ity upon stan­dard­i­s­a­tion of assays. In addi­tion to assess­ing the mod­u­la­tion of the tumour microen­vi­ron­ment within early stages of their research and development.


    Day 1

    • Acti­vated Allo­genec Dcs as an Off-​the-​shelf Vac­cine Adju­vant in Can­cer Immunotherapy
    • Assess­ing the Devel­op­ments in the Field of Can­cer Vaccines
    • Can­cer Vac­ci­na­tion in the Era of Immunomod­u­la­tory Immunotherapy
    • Case Study: Oncolytic Vac­cines — a Step into Can­cer Immunotherapy
    • Phase I/​ii Trial of a Novel Anti­body Dna Immunother­apy, Scib1 Immuno­body Which Tar­gets Cd64, in the Treat­ment of Melanoma
    • Ther­a­peu­tic Vac­cines for the Treat­ment of Can­cer — Where Are We Now?
    • T-​cell Immune Mon­i­tor­ing: Reli­a­bil­ity, Stan­dard­i­s­a­tion and Use in Clin­i­cal Trials
    • T-​vec – Oncolytic Immunother­apy in Metasta­tic Melanoma

    Day 2

    • A Per­fect Part­ner­ship — a Uni­ver­sity of Penn­syl­va­nia and Novar­tis Collaboration!
    • Assess­ing Reg­u­la­tory Approval and Clin­i­cal Trial Design
    • Biomarker-​guided Devel­op­ment of Novel Can­cer Vac­cines– from Off-​the-​shelf to Actively Personalised
    • Head and Neck Can­cer Immunother­apy: Trans­lat­ing Lab­o­ra­tory Sci­ence into a Clin­i­cal Program
    • High Expec­ta­tions and Har­ness­ing the Body’s Immune System
    • Proac­tive Issue of Tumor Genomic Het­ero­gene­ity in Immunotherapy
    • Rnac­tive® for Can­cer Immunotherapy
    • What Are the Key Ques­tions in Can­cer Immunotherapy


    • Alex Karlsson-​Parra – CSO, Immu­nicum AB
    • Bir­git Scheel – Direc­tor Pro­gram Man­age­ment Oncol­ogy, Cure­vac GmbH
    • Chris­t­ian Ottens­meier – Pro­fes­sor in Exper­i­men­tal Can­cer Med­i­cine, Uni­ver­sity Of Southamp­ton, United Kingdom
    • Emma King – CRUK Senior Lec­turer in Head and Neck Surgery, Southamp­ton Uni­ver­sity, United Kingdom
    • Harpreet Singh – Man­ag­ing Direc­tor, Founder and CSO, Immat­ics Biotech­nolo­gies GmbH
    • John Bea­dle – Chief Exec­u­tive Offi­cer, Psioxus Therapeutics
    • Joseph Melen­horst – Direc­tor of the Prod­uct Devel­op­ment & Cor­rel­a­tive Sci­ences Lab­o­ra­tory, Uni­ver­sity Of Penn­syl­va­nia, United States
    • Liselotte Brix – COO, Immudex
    • Madiha Der­ouazi – CEO Amal Therapeutics
    • Tom Lil­lie – Ther­a­peu­tic Area Head, Oncol­ogy, Amgen Ltd

    Ben­e­fits of Attending

    • An excel­lent start­ing point for world­wide benchmarking
    • Hear the lat­est reg­u­la­tory insight into mar­ket approval and clin­i­cal trial design
    • Eval­u­ate case stud­ies from lead­ing aca­d­e­mics and indus­try professionals
    • Assess Strate­gies to enable pos­i­tive devel­op­ments in the field of Can­cer Vaccines

    How should attend?

    • Pro­fes­sor of Oncology
    • Pro­fes­sor of Immunochemistry
    • Pro­fes­sor of Can­cer Med­i­cine and Med­i­c­i­nal Oncology
    • Pro­fes­sor of Exper­i­men­tal Immunology
    • Direc­tor of Immunopharmacology
    • Med­ical Asses­sor, Bio­log­ics Licensing
    • Sci­en­tist, Tumour Immunology
    • Head of Clin­i­cal Analysis
    • Direc­tor of Research
    • Con­sul­tant in Med­ical Oncology
    • Head of Immunology
    starting: ending: 16.09.2014 Location: , Category:


    Conference START 16.09.2014 END

    We are sorry,
    but at the moment we don't have any contact information to perform neither abstract, paper submission nor registration.

    Please check back later...

    Conference Facts

    Location , Address Carburton Street 5 Category More Info Conference Website

    Further interesting Conferences

    Currently we have no similar events listed. Please check our website regulary, subscribe to our RSS-Feed or follow us on twitter for new listings.